{"id":892112,"date":"2025-10-02T17:24:56","date_gmt":"2025-10-02T21:24:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/"},"modified":"2025-10-02T17:24:56","modified_gmt":"2025-10-02T21:24:56","slug":"cardiff-oncology-to-participate-in-two-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/","title":{"rendered":"Cardiff Oncology to Participate in Two Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Oct.  02, 2025  (GLOBE NEWSWIRE) &#8212; Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025.<\/p>\n<p>Details of the events can be found below.<\/p>\n<p>\n        <strong>Piper Sandler Virtual Oncology Symposium <\/strong><br \/>\n        <br \/>Format: Fireside Chat <br \/>Presenters: Mark Erlander, PhD (CEO), James Levine (CFO), and Roger Sidhu, MD (CMO)<br \/>Date: 10\/09\/2025<br \/>Time: 1:00 PM ET<br \/>Contact Piper Sandler for information on attending the conference.<\/p>\n<p>\n        <strong>Noble Capital Markets\u2019 Emerging Growth Virtual Equity Conference <\/strong><br \/>\n        <br \/>Format: Fireside Chat <br \/>Presenter: Mark Erlander, CEO<br \/>Date: 10\/09\/2025 <br \/>Time: 2:00 PM ET<\/p>\n<p align=\"justify\">Interested parties can register for the Noble Capital Markets\u2019 Emerging Growth Virtual Equity Conference at no cost here:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vl_LtZOTKMvkpKZCbm4g72NJ8X2cJ7uYe0nA-XA4Mc1adnC_HQcSmdDzsYxW05tT4yWZYkC3Cxv4Nhn8MCq-VHYA_1Q7OfteQwkzudNkFapzCUjQA-OnihFSpBgaNRIctO2uGwEOPM-WEnpd0YPz0DAVELlYBfYL7ZdySf8flVdA2wNTwg3gajPk5FG2rUs2RzkonexeZm6rtdIK-EslarAXIdLjIlBZo3drNRNoWMh7CNKTXPMzM2Pv1z68igmMJBM_4rreIyNtzchdDMMN6WYOoj5zd6mvYmncJmW94T7odiI__LVdeOEsIM273PLT6Xk8S4miyDgkqHw6mmVl3UtaA8ZuPBHys5oIsaXCu2R9Z1-e60V8aaE25DpP1HSGVzGpqhR0sLuRbn2hlmvhnNeiV2HgrRMfBy790VzN0ybMEFIOJaiM4b5CYl6tlS-8wrLzhFUk0ZuBJXsDjhSJ6vxpKtUAebggFUl2O7ofYphidcOo7E_IJUPLP8w5WXh_\" rel=\"nofollow\" target=\"_blank\">Virtual Equity Conference Registration<\/a>. The webcast replay will be available within 48 hours of the conclusion of the presentation on the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RwCD0b6y193M83174oOrJNlpcng7OdbK5E7yOcViWgu--LlDnsQ7mtrnyc8A24oANJQZewR6RWlI9Ye2CGeWQmL0cH_hxA4i0hkBLLSP1ke5xfdBnD2w9s2988B2PkWCT1GNJdPOV4Meelef1YmiYilBpIAi1OHJPvi_Ra8DVIfrg0JgKSqHXppF-XdEUhpHaaxJWMRxcmFGJe6VQv2S98lL3VzXAqJqjaFqsWimMKS5v8r6vx-m9ltjwcEaY1b2cT4ZaS7EUiLs6HOJtEb98MuXZMhVwyBnf2ftjaxvjfVkWiwDPXD_Ram3sNVMcR1RVThKY_jtv859Uc8HNKitmeKPbbwEalSAqP2Djgm_UKTzqgZpUlLE1lbkM8VsqgakoBKb158OWdgfnqVohK0JldUBGCYmRUCB_Ty7hA5nMWA=\" rel=\"nofollow\" target=\"_blank\">Events<\/a>\u201d section of the Cardiff Oncology website.<\/p>\n<p>\n        <strong>About Cardiff Oncology, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company&#8217;s lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as\u00a0RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company&#8217;s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AlD9AvLCHZMgnAWLFBpe9EZ5xyT8JFI-QjHao2mO68p4bHDK9f6y4ITIdWv1NlM9elC22IwRdbdruCdWb8mzBkyjj8w84f7UV9nWtfUDIYoi0Ap45LG0MucHSdiZdr9-pgMJ_VuXqxEoDcIc_dFXPwcdjhTyvA_oEZIAMFh1VkoNoFz67a6Tv6x2NSSexQjbIMQWtZ2s281je57sdLRVrhx4TbJvTNIZNPLiuJr_fLTdkJgHpzg2xBLgF5-QINoGu0E0qhwXMHivjuiN-mbx1IsGCnP3_Gy6vms800KiEZZSNjKEyavqaFlcw_X47dKM6DHHux1ob15qU57fswo_UzHtP4ENGTu1A37wrZkFtD7TFDggyz-yczSQyofel3GavCEr11QTPRj6XtTRhm-54mWJaZux76ba3prlarnvQpwJTWhY9cPjSD1zGW37ijxX0TU3NS_8wZOJZ1JDoa_lfXV7xA4BH6TH-gZrAFGcOzSAPEGoXgMIOyUZxHN836HahS1cDLzSV4SuIFs7Y1Rh6XuZCNCuP_EXsamllPLgIIcOsROPj3cOMZzG76Msu-fLpzHw_Axt3e7pcKNFYod16D7wzS6z_GP2aYyzOOYR3tGIzxBTGdHHqO3FuJ2Ju_Ox_00jAInaRnkTxeonoUqrCp0bUXPrnDWSNRJlcRPk2s0BlwkYk-Fd1B8q-UB9DkiGGAM6WypC6LHbq2CWEt4yL-dgSzght_GDUb2jAXLairpI4Bh866sSNUR4rQBPpbr1D8aU955S0vxwxRdB-COgmkBh-pW_1kkrzFBYIGMXjINZSrCEKXwFUBskfFypLIC11fd8cdSk32mjW7pVDNiIrO7uiNKckzjmK_7v99iHEDQAr_NVKCWhp-UQJ1rQxHQJXug04pGkVH240mEF3dR71PIVmiL77p1Mgd0z5zfbyUEgc0HwCGzInRr7t3rutbrp6j9krCEN6FwEM6cP6Km88P7W3P9QUOLabqmSi6nf8lopvxHYhUaxdgh1o4Z4LK_hvAP17wnOT2TiLWZ_oGHo0gm2QnGxys6lFlLvOroCrsdH6RvtCuea_q2iUJHJ0g4mBjDnUI8udcoxvjUGojWhMDV2sOVRxm8OFdTZsrbtyVnX3o24AVkehjvm0jCZ55IThfRM6Og2nfhc7neiIsrBm7eBWxZ5ArtJ5ISqUvkjuqnWTyjEJ7HWXnzRNXTNoDeYyZLBJLr5GpcKjsPOrwfAAmT4l8Xc-Q-btbBCqXtc1pLs9mlJeAdknA0VslXisNAtR3fKsz6j6qtJlNA1RRNZNksfVYNTkJkVYt_nqDsPxYNV7EN-JckctQd4oj1JnH-vPF-XRYfftVibidgQtvhHKzTcaNTCn6j2eCXdfD-stIhcHfQLJbGTGgZd0hZw1pcJwAREl-UnIi8TjcCr0cPHW0fkjqv8YtHNiHVNu_T_DVHABx8B-o76YH6pvMICnhO29Nr2huoRocKrdYqbZds8Zi9108oOCJySZngkFo6FFsv4SXMDp19gHNWPs2xaQEOBeCGua4d8957zisg6clOFdoIFxjRN_5XFbWnJAVc1Ckt0dXIW68Dbyl4rWT-YZFUy4nKlzA9_-rlIH_P2RGluGeh2qHRKRZ1nfL-YqhkJoia5kToLUhMLZPMEQ7xXcVIZHszVqsT5irSe1_jM2ZM9wggFbmPHr28-FijmbO8Ro1oMLoDi8_AaFAFVkxfiA_7pEj6CAB-fF9KfzBDGZMd7mcq8Gvs2rKBsZ5ywxbf4FdOzZvtPN_Su3VFeBK0Pc-WC9In13vkMVM-_Xkz5h-H-knKacOfOYyRlYxG7MsIkbWvA3MgSGGHt1mEcZYaCe90_J5AeFYK0uipaBBfAzXj4cJRVj7sygBtZdaNXi1sI7JoUCX0kwSVNqcpGpXOozgBLTtfpFvM85LRQWvdKL4QGjDVy9Qs0N_UQ_VGKOA3r0BCyUDEZUA8-Tz827Lx5qLIxnmYuFtNUxazQ3EVfqQaOJcfT61edIg2JPcW0o7xTgP3ST0ozOH5oKzxxvrcUqIlrYNBw8eNNvuu_BHiSoywpmzgEd-4TS7YuxpxPo-XxtFXqBzwKjymBpeMkJQQ8-mnDoAHIDknBTwiVD9dbvBTradd9GucziILwcbdl8wY3xQetCEW_4wbAVHHFgF2ILCXfZU6b69HKV5KmUtPWcsxJaA==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.cardiffoncology.com<\/a>.<\/p>\n<p>\n        <strong>Cardiff Oncology Contact:<\/strong><br \/>\n        <br \/>James Levine<br \/>Chief Financial Officer<br \/>858-952-7670<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T9mH680eJLxFbuBLAwKgctoiXMoqh-P10PEW1cn940x4C_7Bhq4mlFA8HIwHS1Jp8qbFAo17PQ8SD3LQaDqBz8kWj0CB9qFLeadTMybxLIO-s1YBpq7Ky_0djNYjH7k9\" rel=\"nofollow\" target=\"_blank\">jlevine@cardiffoncology.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Kiki Patel, PharmD<br \/>Gilmartin Group<br \/>332-895-3225<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0MTCp5b98rpXKtutFOZSShl4QrGxx1N0PosqiAinNmAS8_yROtIOWzQUYjf3ajkqnlpprzbsW148ckfRhpdtKr5OCzB1EV5-V6Xv-TZsHzk=\" rel=\"nofollow\" target=\"_blank\">Kiki@gilmartinir.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Meghan Bianco<br \/>Taft Communications, a division of RF|Binder<br \/>609-544-5446<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Nr5If4XJHzjy38Op36GeM6UQkygx6XmigTfMqA6OaRFtVmmE0ovd3p_Af6sKK1opAQ7C1-maoqWgC5sK3-gJHyZFZn4_eohEa-Usg4lm3-8b3AJ0IptkNWophYRVe7AH\" rel=\"nofollow\" target=\"_blank\">meghan.bianco@rfbinder.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzODg1MSM3MTc1ODY0IzIyNTc1MDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjlhMThhYTctY2FkYS00NTg4LTg4N2UtNmU5ZWI0NzkwMzExLTEyNjkwNTItMjAyNS0xMC0wMi1lbg==\/tiny\/Cardiff-Oncology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) &#8212; Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025. Details of the events can be found below. Piper Sandler Virtual Oncology Symposium Format: Fireside Chat Presenters: Mark Erlander, PhD (CEO), James Levine (CFO), and Roger Sidhu, MD (CMO)Date: 10\/09\/2025Time: 1:00 PM ETContact Piper Sandler for information on attending the conference. Noble Capital Markets\u2019 Emerging Growth Virtual Equity Conference Format: Fireside Chat Presenter: Mark Erlander, CEODate: 10\/09\/2025 Time: 2:00 PM ET Interested parties can register for the Noble Capital Markets\u2019 Emerging Growth Virtual Equity Conference at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cardiff Oncology to Participate in Two Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-892112","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cardiff Oncology to Participate in Two Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiff Oncology to Participate in Two Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) &#8212; Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025. Details of the events can be found below. Piper Sandler Virtual Oncology Symposium Format: Fireside Chat Presenters: Mark Erlander, PhD (CEO), James Levine (CFO), and Roger Sidhu, MD (CMO)Date: 10\/09\/2025Time: 1:00 PM ETContact Piper Sandler for information on attending the conference. Noble Capital Markets\u2019 Emerging Growth Virtual Equity Conference Format: Fireside Chat Presenter: Mark Erlander, CEODate: 10\/09\/2025 Time: 2:00 PM ET Interested parties can register for the Noble Capital Markets\u2019 Emerging Growth Virtual Equity Conference at &hellip; Continue reading &quot;Cardiff Oncology to Participate in Two Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-02T21:24:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzODg1MSM3MTc1ODY0IzIyNTc1MDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cardiff Oncology to Participate in Two Upcoming Investor Conferences\",\"datePublished\":\"2025-10-02T21:24:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\\\/\"},\"wordCount\":315,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzODg1MSM3MTc1ODY0IzIyNTc1MDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\\\/\",\"name\":\"Cardiff Oncology to Participate in Two Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzODg1MSM3MTc1ODY0IzIyNTc1MDM=\",\"datePublished\":\"2025-10-02T21:24:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzODg1MSM3MTc1ODY0IzIyNTc1MDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzODg1MSM3MTc1ODY0IzIyNTc1MDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardiff Oncology to Participate in Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cardiff Oncology to Participate in Two Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Cardiff Oncology to Participate in Two Upcoming Investor Conferences - Market Newsdesk","og_description":"SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) &#8212; Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025. Details of the events can be found below. Piper Sandler Virtual Oncology Symposium Format: Fireside Chat Presenters: Mark Erlander, PhD (CEO), James Levine (CFO), and Roger Sidhu, MD (CMO)Date: 10\/09\/2025Time: 1:00 PM ETContact Piper Sandler for information on attending the conference. Noble Capital Markets\u2019 Emerging Growth Virtual Equity Conference Format: Fireside Chat Presenter: Mark Erlander, CEODate: 10\/09\/2025 Time: 2:00 PM ET Interested parties can register for the Noble Capital Markets\u2019 Emerging Growth Virtual Equity Conference at &hellip; Continue reading \"Cardiff Oncology to Participate in Two Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-02T21:24:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzODg1MSM3MTc1ODY0IzIyNTc1MDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cardiff Oncology to Participate in Two Upcoming Investor Conferences","datePublished":"2025-10-02T21:24:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/"},"wordCount":315,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzODg1MSM3MTc1ODY0IzIyNTc1MDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/","name":"Cardiff Oncology to Participate in Two Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzODg1MSM3MTc1ODY0IzIyNTc1MDM=","datePublished":"2025-10-02T21:24:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzODg1MSM3MTc1ODY0IzIyNTc1MDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzODg1MSM3MTc1ODY0IzIyNTc1MDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cardiff Oncology to Participate in Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=892112"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892112\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=892112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=892112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=892112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}